Sage, Biogen

Sage rejects Biogen’s $469m takeover bid
Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of shareholders.
Sage rejects Biogen's $469 million takeover offer
Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it received from Biogen. The company said Biogen's offer to buy all outstanding shares of Sage that it does not already own for $7.
Sage rejects Biogen takeover and launches review
Since then, Biogen decided to opt out of their partnership on essential tremor candidate SAGE-324 after disappointing results in the mid-stage KINETIC 2 study, while Sage has reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease.
Sage rejects Biogen’s buyout offer, but says it's open to deals
Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen Inc.
Sage Rejects Biogen’s Unsolicited Offer, Will Seek Strategic Alternatives
Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the embattled biotech at just $469 million.
Sage Therapeutics Rejects Biogen’s $469M Offer, Citing Undervaluation
Sage Therapeutics announced its boards unanimous rejection of Biogens $469 million acquisition offer, stating the proposal significantly undervalues the company and does not align with shareholder interests.
Sage Rejects Biogen's $469 Million Takeover Offer, Says Offer Undervalues Company
(Reuters) -Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve shareholders' best interests.
Sage Therapeutics Explores Alternatives, Rejects Biogen's Proposal, Stock Up
The proposal sought to acquire all outstanding shares of Sage not already owned by Biogen for $7.22 per share, a valuation deemed insufficient by the Board. Meanwhile, Sage remains committed to its mission of making ZURZUVAE the standard treatment for women with postpartum depression as the Board evaluates potential strategic opportunities.
Soccer-Lyon sack coach Sage amid poor run
Olympique Lyonnais have sacked coach Pierre Sage, the French Ligue 1 club announced on Tuesday, after a winless run of five ...
Lyon coach Pierre Sage has been fired despite putting the French league club back on track
Lyon coach Pierre Sage has been fired by the French league club. His dismissal followed a 1-1 draw with Nantes over the ...
Ligue 1: Lyon Sack Head Coach Pierre Sage After Nantes Draw Leaves Them 17 Points Adrift Of Leaders PSG
Sage joined Lyon in November 2023 in an interim role, which was made permanent with a contract until 2026 after he led them ...
Sage Group falls Monday, underperforms market
Sage Group PLC SGE shares inched down 0.34% to £13.26 Monday, on what proved to be an all-around favorable trading session ...
FiercePharma6d
Sage sues Biogen as analyst detects little interest in buyout at original offer price
Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience ...
TaxBandits Strengthens Its Partnership with Sage Intacct for Another Successful Season of 1099 E-filing
ROCK HILL, SC / ACCESS Newswire / January 27, 2025 / With the January 31, 2025, deadline for 1099 filing approaching, TaxBandits, an authorized ...